


## Supplemental Figure 1




**Supplemental Figure 1. Variable Degradation Pattern in Dendritic Cells, Macrophages and CD4 T Cells.** HIV p24-35mer (MVHQ AIS PRTLNAWVKVVEEKAFSPEVIPMFAALS, aa 10-44 in Gag p24) was incubated at 37 degrees with DC, macrophage or CD4 T cell extracts for 60 minutes at pH4.0. Degradation products were analyzed by mass spectrometry and aligned to the original p24-35 sequence.

## Supplemental Figure 2



**Supplemental Figure 2. HIV PIs Alter HIV p24 Degradation Pattern.** Full HIV p24 protein was incubated at 37 degrees with DC extracts for 60 minutes at pH4.0. Degradation products were analyzed by LC-MS/MS and the contribution of the cleavage of each amino acid position (N-ter and C-ter) to the total intensity of all degradation products was quantified. The upper panel represents the cutting site intensity at each amino acid location of full HIV p24 protein by DC without PI treatment. The lower panel shows a heat map representing the difference in cutting intensity at each amino acid location of HIV full p24 protein by DCs treated with 5  $\mu$ M of different PIs compared to control.

### Supplemental Figure 3



**Supplemental Figure 3. HIV PIs change p24-161 degradation patterns and epitope production in lysosomal compartments.** (Top panel) HIV p24-161 sequence with the known MHC-II epitope locations in this region. (Middle panel) Cleavage pattern of p24-161 incubated with DC cell extracts for 60 minutes at pH4.0. (Lower panel) Heat map representing the difference in cutting intensity at each amino acid location of p24-161 by DCs treated with 5 μM of SQV or NFV compared to control. Data are representative of three independent experiments with three different donors' DCs analyzed by MS twice each.

## Supplemental Table 1

**Supplemental Table 1: Peptides eluted from SQV treated and untreated PBMCs and their protein of origin.**

Top tables represent the peptides commonly present on treated and untreated PBMCs. Bottom left table represents peptides uniquely present on untreated PBMCs. Bottom middle table represents peptides uniquely present on SQV treated PBMCs. Blue cells are the proteins represented uniquely in control and pink proteins represented uniquely in SQV treatment.